UBS Assumes Coverage of PTC Therapeutics at Buy, Raises Target to $90
UBS assumed coverage of PTC Therapeutics with a Buy rating and raised its price target to $90 per share from $80.
Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
1 result loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
UBS assumed coverage of PTC Therapeutics with a Buy rating and raised its price target to $90 per share from $80.